| HOME >> BIOLOGY >> TECHNOLOGY |
decision to change manufacturing processes.
(c) To exclude the ongoing, non-cash amortization of the R&D technology
intangible assets acquired with the acquisitions of Abgenix, Inc.
("Abgenix") and Avidia, Inc. ("Avidia").
(d) To exclude the ongoing, non-cash amortization of acquired product
technology rights, primarily ENBREL, related to the Immunex
Corporation ("Immunex") acquisition.
(e) To exclude the following restructuring (expenses)/recoveries
associated with our restructuring plan announced in August 2007, as
follows (in millions):
Accel-
Separ- Asset erated
ation impair- deprec-
costs ment iation
(1) (2) (3) Other(4) Total
------- -------- ------- -------- ------
Three months ended
September 30, 2008
-------------------------
Other charges $- $(1) $- $(7) $(8)
------- -------- ------- -------- ------
$- $(1) $- $(7) $(8)
======= ======== ======= ======== ======
Three months ended
September 30, 2007
-------------------------
Cost of sales (excluding
amortization of
intangible assets) $1 $(4) $(110) $- $(113)
Research and development
(R&D) 17 (35) - - (18)
Selling, general and
administrative (SG&A) 9 - - 83 92
Other charges
'/>"/>
| SOURCE Amgen Copyright©2008 PR Newswire. All rights reserved |